Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
NCT06409689

Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study

Led by Tongji Hospital · Updated on 2025-01-03

80

Participants Needed

1

Research Sites

56 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Identifying the lowest effective opioid dose that achieves rapid pain relief while minimizing side effects is a principal objective in postoperative multimodal analgesia strategies. This study aims to determine the optimal analgesic regimen and dosage by assessing the clinical efficacy of oliceridine for postoperative pain management. It also evaluates oliceridine's contribution to accelerated postoperative recovery, examining aspects such as postoperative pulmonary complications, gastrointestinal function, nausea and vomiting, cognitive function, and emotional distress. Furthermore, the study integrates microbiomics and metabolomics to investigate the underlying molecular mechanisms by which oliceridine promotes rapid postoperative recovery. This research will broaden the clinical data and potential applications of oliceridine, addressing gaps in the field and enhancing practical knowledge. Moreover, this is the first time a clinical study combining multiple omics approaches will provide a comprehensive theoretical foundation for its clinical benefits.

CONDITIONS

Official Title

Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • ASA physical status grades 1 or 2
  • Age over 18 years and under 70 years
  • Scheduled for laparoscopic upper abdominal surgery under general anesthesia with operation time no more than 4 hours
  • Willing to receive postoperative controlled intravenous analgesia
  • Able to understand and cooperate with study procedures
  • Able to provide and sign written informed consent before study screening
Not Eligible

You will not qualify if you...

  • Body mass index (BMI) over 30 kg/m2 or under 19 kg/m2
  • Preoperative opioid use or presence of acute or chronic pain or increased sensitivity to pain
  • History of coronary atherosclerotic heart disease, significant ischemic heart disease, severe angina, heart failure, valvular or other heart diseases
  • Severe liver or kidney insufficiency
  • History of mental illness or alcoholism
  • History of alcohol or drug abuse
  • Conditions with increased cranial pressure, intraocular pressure, or glaucoma
  • Poorly controlled or untreated hypertension before surgery
  • Presence of preeclampsia or eclampsia
  • Untreated or undertreated hyperthyroidism
  • Presence of autoimmune disease
  • Inability to use the numerical rating pain scale
  • History of chronic cough
  • Expected surgery duration over 4 hours
  • Participation in other clinical trials within the last 3 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tongji Hospital

Wuhan, Hubei, China

Actively Recruiting

Loading map...

Research Team

H

Hui Xu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here